Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

Carboplatin 31Pemetrexed 28Radiotherapy 22Bevacizumab 21Cisplatin 20Gemcitabine 18Paclitaxel 17Erlotinib Hydrochloride 15Docetaxel 12Gefitinib 8Nivolumab 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6pembrolizumab 5aflutinib 5Radiosurgery 5tislelizumab 4Vinorelbine 4Surgical Procedures, Operative 4Specimen Handling 4Sorafenib 4Platinum 4Metformin 4Biopsy 42-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 4sargramostim 3apatinib 3Taxes 3Cetuximab 3Anterior Temporal Lobectomy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma of Lung × tislelizumab × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04310943 2024-03-06

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

Guangzhou Institute of Respiratory Disease

Phase 2 Completed
24 enrolled
Thoracic

Adenocarcinoma of Lung

NCT06056115 2023-09-28

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Hebei Medical University Fourth Hospital

Phase NA Recruiting
20 enrolled
Thoracic

Adenocarcinoma of Lung

NCT05527808 2023-06-08

A Single-arm Exploratory Study of Neoadjuvant Therapy

Guangzhou Institute of Respiratory Disease

Phase NA Unknown
28 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡